anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Known compositions comprising an immunoglobulin suffer the problem that the presence of aggregated molecules of immunoglobulin can cause anaphylactic side effects. S-sulfonation of an immunoglobulin provides a safer product having fewer side effects but aggregated molecules are still present. …&lt;??&gt;The invention provides a composition having a reduced concentration of aggregated molecules comprising an S-sulfonated immunoglobulin and, as an aggregation preventing or aggregate dissociating agent therefor, 1 to 600% by weight, based on the weight of the S-sulfonated immunoglobulin, of a water-soluble acid addition salt of a basic nitrogen-containing organic compound containing one or more basic nitrogen atoms in the molecule and having a pKb at 25 DEG C of not more than 7. The composition can be used for the intravenous administration of an immunoglobulin or can be lyophilized. …&lt;??&gt;Compositions containing a high proportion of monomeric S-sulfonated immunoglobulin can be prepared by contacting an S-sulfonated immunoglobulin in aqueous solution with 1 to 600% by weight, based on the weight of the S-sulfonated immunoglobulin, of the water-soluble acid addton salt, or by reacting @ immunoglobulin in aqueous solution with a compound capable of yielding a sulfite ion in water and an oxidizing agent in the presence of 1 to 600% by weight, based on the immunoglobulin, of the water-soluble acid addition salt.
PURPOSE: To obtain an anhydrous manicure excellent in stability with time, luster and excellent to keratin of nail, containing a specific resin in a solvent for manicure free from nitrocellulose. CONSTITUTION: This non-nitrocellulose manicure contains a resin which contains a resin in a solvent for manicure. The resin comprises a motif (unit) formed by copolymerization of 20-70% of at least one hydroxyalkyl (meth)acrylate of formula I (R&#39; is H or CH3 ; R is a 1-6C saturated hydrocarbon group) and 30-80% of at least one hydroxyalkyl (meth)acrylate of formula II (R1 =R&#39;; R2 is a hydrocarbon group containing a 2-4C and one or two OH groups). The copolymer does not comprise 30% or more of the unit derived from the copolymerization. The resin has &gt;=0.1Pa. s viscosity in 28% ethyl acetate solution at 25 deg.C. A packed material comprises two parts of the manicure and an alcohol or its mixture.
FIELD: medicinal microbiology. SUBSTANCE: for preparing leptospirosis vaccine no containing rabbit protein new strain Leptospira interrogans &#34;Rat 2&#34; НИИЭМ No. 466 is proposed. Strain is able to multiply actively on semisynthetic medium with human protein and shows stable virulence and high immunogenicity. Leptospira strain allows to prepare leptospirosis vaccine purified off mammalian protein showing high antigenic and protective properties for human immunization against interohemorrhagic leptospirosis. EFFECT: improved method of vaccine preparing. 1 tbl
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an ideal drug for controlling labor pain and treating premature birth which can adjust initiation of labor pain to control the term of delivery, is effective for a patient of premature birth, and does not adversely affect a fetus when administered.  &lt;P&gt;SOLUTION: An expression plasmid is obtained by connecting a cDNA which codes ORF of soluble form of human P-LAP to the Hind III site of a pdKCR-dhfr vector. Then, gene introduction into Chinese hamster ovary(CHO)-dhfr-cells is performed utilizing this expression plasmid. Thereafter, the gene-introduced cells are maintained in an α-mineral essential medium, and then a resistant clone is selected, and the resistance clone is multiplied to obtain a predetermined amount of a soluble form of P-LAP. Subsequently, when the obtained P-LAP is administered to a pregnant mouse to count the period between pregnancy and childbirth, it has been found that the administration of P-LAP tends to extend the period of pregnancy.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
As disclosed herein, sotorasib augments the KRAS-G12C mutant cancer cells response to TNFα by increasing TNFR1 surface expression, which in turn upregulates TNFα and IFNγ down-stream target genes and ultimately enhances cancer cell death. In TACE-dependent mechanism, Sotorasib inhibited TNFR1 shedding off the KRAS-G12C mutant cancer cells. Additionally, Sotorasib significantly promotes the expansion of tumor infiltrating lymphocytes (TILs). In addition, it generates a &#34;hot&#34; tumor microenvironment with strikingly augmented T cell effector phenotype. These results suggest that sotorasib regulation of TNFα and IFNγ plays a crucial role in generating a more immune active tumor microenvironment. Consistently, sotorasib combined with CAR-T adoptive cell transfer and anti-PD1 treatment enhanced their anti-tumor effect. Therefore, disclosed herein is a method for treating KRAS-G12C mutant cancer in a subject, the method involving adoptively transferring an effective amount of autologous or allogeneic immune effector cells (T cells) to the subject in combination with a KRAS-G12C inhibitor.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a cosmetic that has high safety, excellent stability and high transparency and to provide a method for producing the same.  &lt;P&gt;SOLUTION: The method for producing the cosmetic comprises a dispersion process with which a mixed solution containing at least lecithin, an oil and fat component and a polyhydric alcohol is accelerated and made to collide with each other under high pressure so as to finely disperse the oil and fat component into an aqueous solvent. The pressure under which the mixed solution is accelerated and made to collide with itself is ≥21MPa. The dispersion process is repeated a plurality of times. The method for producing the cosmetic has a mixing process with which at least the lecithin is mixed with the oil and fat component and the polyhydric alcohol before the dispersion process.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a therapy in the field of immunology, more specifically cancer immunotherapy, and particularly, combined immunotherapy and a therapeutic method for inhibiting growth of tumor cells and/or removing tumor cells.  &lt;P&gt;SOLUTION: The method is based on inhibiting receptors having protein kinase activity in tylosin residues (receptor tyrosine kinase, RTK) and ligands of these receptors. The combined immunotherapy is defined as a treatment for inhibiting the RTK receptors and/or their ligands by the combined use of passive and active immunity therapies. The described procedure can be applied to a patient in various clinical stages of a tumor derived from an epithelium which excessively expresses these receptors. The combined use of active and passive immunity may be performed simultaneously or successively irrespective of whether the treatment procedure is used for a patient in advanced stages of disease or it is used as an auxiliary treatment.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a safe and stable percutaneous absorbefacient composition exhibiting not only percutaneous absorbefacient effects but also excellent skin permeability even for a drug having relatively high lipophilicity with poor percutaneous absorptivity and having excellent feeling of use and to provide a percutaneous absorption preparation comprising the composition and a drug.  &lt;P&gt;SOLUTION: The percutaneous absorbefacient composition comprises the following ingredients (a), (b) and (c). The percutaneous absorption preparation comprises the following ingredients (a), (b), (c) and (d). The ingredient (a) is propylene glycol and the ingredient (b) is a polyol fatty acid ester. The ingredient (c) is lauromacrogol and the ingredient (d) is the drug.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
A whitening system for a person&#39;s teeth includes a gel having a whitening agent, such as peroxide, contained therein. The gel is supported and carried in a channel formed in the central area of a strip of core material that also functions as a gum protective liner. The core and gum protective liner is preferably made of a biodegradable material or of a similar material that can be washed or brushed away. A release liner may be applied to the top of the combined gel and core and is removed to expose the gel when the system is to be used. Applied to the lower side of the core is a releasable backing layer that supports the gel and core and functions as an applicator for the system. The backing layer maintains the integrity of the core and allows the same to be molded to the surfaces of the teeth without having to directly handle the core with one&#39;s hands. To use the system, the release liner is removed and the core is fitted to the teeth with the gel in contact with the teeth and the gum protective liner covering the gum. Once the core has been fitted to the teeth, the backing layer is removed leaving the core in place with the gel and whitening agent remaining on the teeth. After a desired period of time, the core with the whitening gel is washed off, brushed off, pulled off, or is allowed to simply dissolve.
1,129,277. Collagen sponge. ETHICON, Inc. 16 March, 1966 [25 March, 1965], No. 11610/66. Heading A5R. [Also in Division C3] The invention comprises an odourless, water permeable, water insoluble sponge consisting essentially of collagen fibrils, the sponge being substantially free of an acid having a dissociation constant in aqueous solutions greater than 4.90 x 10&lt;SP&gt;-7&lt;/SP&gt; at 35‹C and a salt of such an acid. The collagen sponge may be made by swelling collagen fibrils in an aqueous solution of an acid or a salt thereof at 0-35‹C, the acid having a dissociation constant in aqueous solution greater than 4.90 x 10&lt;SP&gt;-7&lt;/SP&gt; at 35‹C, homogenising the swollen collagen to form a uniform mass, shaping the mass into a desired form, and lyophilising the shaped mass to form the sponge. The preferred acid is carbonic acid. The sponge may be tanned by contacting with formaldehyde vapour at 20-140‹C and may be sterilised by exposure to γ rays.
&lt;P&gt;PROBLEM TO BE SOLVED: To detect and collect time of dosage of internal test medicine for new developed medicine clinical trial easily.  &lt;P&gt;SOLUTION: The case for test medicine 1 has a plurality of areas for a dosage of the internal clinical trial medicine. The lid for each area is sealed with a noncontact electronic tag 2. When a user opens the lid for clinical trial medicine to take the internal clinical trial medicine, the antenna part of the noncontact electronic tag 2 is cut off. When the case for clinical trial medicine 1 is returned into the storing box 3 where a reader 4 is built-in and the storing box 3 is closed, the reader 4 communicates with the noncontact electronic tag 2 and records the received data and the communication time. The final communication time of the noncontact electronic tag 2 is calculated to obtain the time of dosage of the internal clinical trial medicine 1.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a lactic fermentation product of soybean having high immunoenhancing effect and good taste.  &lt;P&gt;SOLUTION: Soybean or its processed product is fermented by the coculture of lactobacillus and yeast. The lactobacillus at least contains Enterococcus faecalis properly combine with other cocci, bacilli or bifidus bacteria. The yeast is Saccharomyces cerevisiae and/or Saccharomyces rosei. The fermented soybean is produced by fermenting soya milk with the above microorganisms and the produced fermented liquid is neutralized with a calcium compound and dried to obtain a powdery fermentation product.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE:To obtain water and oil repellent powder being excellent in water and oil repellency and being good in the touch after use, especially excellent in smoothness by treating a surface of powder with N-mono (long chain) acyl basic amino acid and a compd. contg. perfluoroalkyl group having a more carbon number than a specified number. CONSTITUTION:Powder is surface treated with following chemicals a) and b) to obtain the water and oil repellent powder. Chemicals a): N-mono (long chain) acyl basic amino acid having one aliphatic acyl group of a straight or branched 8-22C chain in a molecule, chemicals b): chemicals selected from a group of compds. (b-1) to (b-4) shown hereunder, compd. (b-1): an epoxy compd. having a perfluoroalkyl group of a straight or branch &gt;=6C chain, compd. (b-2): a silane compd. having a perfluoroalkyl group of a normal or branched &gt;=6C chain, compd. (b-3): a titanium compd. having a perfluoroalkyl group of a straight or branched &gt;=6C chain, compd. (b-4): a polysiloxane compd. having the same condition as the above-mentioned.
Systems and methods are provided for measuring performance improvements within clinical facilities. An optimized practice process model may be defined for a particular clinical procedure, setting forth an optimal clinical process. In addition, critical levers may be identified within the optimal clinical process, representing the activities that have the greatest impact on outcomes. Clinical facilities may collect current measures for the critical levers, and the current measures may be compared against an optimal, benchmark, and/or target measure. Based on the comparison, opportunities for clinical process optimization may be identified. Those opportunities may then be analyzed and prioritized for adoption into a facility&#39;s current practice. Performance improvement for a clinical process may be measured by setting previous current measures as baseline measures and comparing new current measures against the baseline measures.
In accordance with the present invention it has been found that a fibrin polymer film formed by applying materials most closely resembling the natural clotting materials to a surgical adhesion formation. Preferred embodiments involve application of a fibrin monomer under polymerizing conditions to the surgical wound site. Unexpectedly, in addition to this improved prevention of adhesions, the more chemically-natural clots, especially the fibrin-monomer based fibrin polymer, also functions as a fibrin sealant, i.e., has adherence, provides hemostasis and promotes wound healing while also functioning as a barrier. In preferred embodiments the novel methods of this invention conveniently use one or more plasma proteins derived from the patient&#39;s own blood as to be autologous. Further, the sealant material is preferably substantially free of any added or exogenous enzymes, e.g., thrombin, etc., which catalyze the cleavage of fibrinopeptides A and/or B from fibrinogen. Preferably a fibrin monomer solution is sprayed over the wounded surgical site.
The present invention relates to the method of increasing the bioavailability of Angiotensin II Receptor Blockers (ARBs) by preparing a composition of an ARB with at least one solubility enhancing agent. In particular, the present invention relates to solubility enhancing agents that not only act as solubility enhancers but also improve the dissolution rate particularly in acidic or mildly acidic media, where solubility of the ARB is minimal. In the composition, the ARB may be present in the form of physical blend, solid dispersion, solid solution or complex with the solubility enhancing agent. The composition of an ARB with solubility enhancing agent can be incorporated in an immediate release or a controlled release or any other suitable modified release formulation. Immediate release dosage forms containing the composition of an ARB give an in vitro release of at least 40% in acidic media (pH &lt; 3). As a result, the bioavailability of the ARB can be increased by at least 20% as measured by Cmax, AUC0-t and AUCo-∞.
PROBLEM TO BE SOLVED: To obtain an oxidative hair dye containing the combination of a specific developing component with a coupling component, having an acidic to neutral pH value and capable of uniformly dyeing hair. SOLUTION: This oxidative hair dye contains the combination of 2-(2,5- diaminophenyl)ethanol or its water-soluble salt as a developing agent with a coupling agent (e.g. 4-chlororesorcinol) in an amount of 0.1-8 wt.% in a hair dye component mixture. Additives such as a direct dye (e.g. picramic acid), an antioxidizing agent (e.g. ascorbic acid), a perfume, a complex-forming agent, a wetting agent, an emulsifier and a thickener are further suitably added. The dye component mixture is mixed with an oxidizing agent (e.g. hydrogen peroxide) in a weight ratio of 5:1 to 1:3 at a pH of &lt;=8, preferably 5.0-6.9, just before used. The dyeing of hair is carried out by coating hair with a sufficient amount of the mixture and subsequently leaving the coated hair at 15-50 deg.C for 10-45 min. A blue color or a red color in addition to a natural color can be developed.
The damage to hair during bleaching and dyeing with compounds yielding active oxygen, e.g. hydrogen peroxide, melamine perhydrate, sodium perborate and sodium persulphate, is reduced by treating it with one or more aminopolyphosphonic acids having the formula: &lt;FORM:1102734/D1-D2/1&gt; in which Z and Y represent a hydrogen atom or an alkyl radical containing 1-4 carbon atoms and R4 and R5 represent a-PO3H2 group or a group having the formula: &lt;FORM:1102734/D1-D2/2&gt; or a water-soluble salt or ester thereof optionally in admixture with a compound having the formula: &lt;FORM:1102734/D1-D2/3&gt; in which X is -OH or NH2, R, is an aryl radical, an aliphatic radical having 1-5 carbon atoms or the radical: &lt;FORM:1102734/D1-D2/4&gt; and R2 and R3 are hydrogen atoms or alkyl radicals having 1-5 carbon atoms, or a water soluble salt thereof. Mixtures containing the aminopolyphosphonic acids and organic acylation products of phosphorous acid in the weight ratio of between 3:1 and 1:3 may be used. Suitable watersoluble salts are the sodium, potassium, ammonium and mono-, di-and tri-ethanolamine salts. The compounds may be applied to the hair before or during bleaching or dyeing as a solution, gel, cream, powder which may also contain thickeners, wetting agents or cosmetic additives, e.g. fatty alcohols containing 12 to 14 carbon atoms, fatty alcohol sulphates containing 16 - 18 carbon atoms, the reaction product of 1 mol of stearyl alcohol with 8 mol of ethylene oxide, paraffin oil, glycerine, ammonia, soda, oxidation dyestuffs and cetyl trimethylammonium chloride.
The present invention provides an inhalation-type pharmaceutical composition for alzheimer&#39;s disease comprising a first gas and a vaporized pharmaceutical liquid. The first gas comprises hydrogen. The hydrogen has a gas volume concentration between 2% and 96% in the inhalation-type pharmaceutical composition. The vaporized pharmaceutical liquid comprises at least one selected from the group consisting of rivastigmine hydrogen tartrate, donepezil hydrochloride, galantamine hydrobromide, and memantine hydrochloride. The inhalation-type pharmaceutical composition of the present invention can remove reactive oxygen, and the vaporized pharmaceutical liquid can improve absorbability in the present invention. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid indirectly reduce the side effects of human.
A computer-implemented method includes receiving information to authenticate an identity of a patient. One or more medical service providers of the patient are identified. An electronic medical record or electronic practice management system is identified for each of the identified medical service providers. The patient&#39;s electronic health record is acquired from each of the identified medical service providers electronic medical record or electronic practice management system. The patient&#39;s acquired electronic health records are aggregated. The patient&#39;s aggregated electronic health records are integrated. A holistic electronic health record based on the patient&#39;s integrated electronic health records are stored.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a drug decreasing or overcoming addiction, and if possible, alleviating or removing the symptoms related to the withdrawal of habit-forming and addictive drugs.  &lt;P&gt;SOLUTION: A composition for use in managing withdrawal from an addictive substance is described. The composition includes one or more peptides having specific activity on εisozyme and/or γisozyme of protein kinase C (PKC). The peptide can be administered prior to, concurrent with or subsequent to administration of the addictive substance. Also there is described a kit having at least one container containing a peptide having isozyme-specific activity on εPKC or γPKC and instructions for use.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To obtain a weakly toxic strain having reduced pathogenicity without losing immunity productivity of virus, by successively subjecting a swine parvovirus to subculture by the use of a bovine skin culture cell at low temperature. CONSTITUTION:A weakly toxic strain separated from wild-type virus is used as a virus. For example, when swine parvovirus 90HS strain (ESK 9 generations, SK 4 generations passage) given from Sericultural Experiment Station of Ministry of Agriculture and Fishery is used as an original strain virus, a bovine fetal skin (BED skin for short) cell is used for passage of virus. The BED cell is prepared by treating skin of bovine fetus with trypsin and cultivating the skin in Eagle&#39;s MEM medium containing 10wt% calf serum. A virus solution is heat-treated at 60 deg.C for 30min and the original strain virus is passaged with a swine liver cell at 37 deg.C by one generation and with BED cell by 6 generations. Successively, the culture temperature is lowered to 32 deg.C and BED cell is passaged to give low-temperature 35 generations passage strain.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a simple method for manufacturing perfume with reduced cost, remarkably shortening time for development of the perfume.  &lt;P&gt;SOLUTION: The method for manufacturing perfume includes a step of preparing diluted solutions of a plurality of perfumes by diluting with organic solvents. The diluted solutions prepared are subjected to a pressurization treatment. The pressurization treatment is preferably carried out under a pressure of 200-1,000 MPa. The perfume emitting fragrance similar to that of a perfume having been subjected to a natural aging for some months is prepared by preserving the pressurized state for some hours.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medical intelligent server architecture for computer-assisted detection, in which extension is possible to cope with an ever increasing number of patients, and service detection can be easily varied or added based on various modalities.  &lt;P&gt;SOLUTION: The architecture comprises dedicated server configuration, providing disease detection service when a set of medical images are provided. The architecture can be combined with an existing medical information system. The architecture for computer-assisted detection is adaptable to variation required by the computer-assisted detection service, and is easily extensible to include new or varied detection service. It is thus extensible to adapt to images from an ever increasing number of patients of various types.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT